Remdesivir is a less popular drug for antiviral medication, which has become the first medicine approved by the FDA for treating the novel Coronavirus in May 2020. Previously, the drug Remdesivir was regarded as an investigational drug. The drug was never used to treat any disease or any medical condition. Today, the drug is being studied as a probable treatment for several diseases. In the beginning, the drug was created as a potential treatment for hepatitis. The drug was studied as a potential treatment for Ebola virus in 2014. Since then, the effectiveness of the drug has been studied as treatment for any other viruses other than the novel Coronavirus. Also, researchers have found that Remdesivir drug has been proved to be effective against several other (SARS) severe acute respiratory syndrome and also (MERS) Middle East respiratory syndrome, despite the studies were done in the test-tubes and not in animals but on animals.
The drug, when used on Coronavirus affected people prevents the virus from creating the specific enzyme that is essential for the virus to copy itself. Once this happens, the virus does not spread in the body of the affected. Also, further research has shown that Remdesivir is efficient enough to shorten the duration of the patients' stay in the hospital. The drug is also associated with less number of deaths, especially among the unwell Coronavirus patients.Major Key Players of the Remdesivir Market are:
Gilead Sciences, Inc., BrightGene Bio-Medical Technology Co.,Ltd., Hainan Haiyao Co., Ltd., EVA PHARM, Cipla Inc., Mylan N.V., Hetero, Ferozsons Laboratories, Zydus Cadila, Dr. Reddy's Laboratories Ltd. and Beximco Pharmaceuticals Ltd., among others.
No comments:
Post a Comment